Therapeutic management of refractory or relapsed primary central nervous system lymphomas

Annals of Hematology, Supplement

Volumn 80, Issue 3, 2001, Pages

  Reni, M ^a   Ferreri, A J M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Brain neoplasms; extranodal lymphomas; Non Hodgkin's lymphoma; Primary central nervous system lymphoma; Salvage treatment

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; METHOTREXATE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

CANCER RADIOTHERAPY; CELL HETEROGENEITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; EYE CANCER; HUMAN; IMMUNOCOMPETENT CELL; MENINGIOMA; NEUROTOXICITY; PERIPHERAL BLOOD STEM CELL; PRACTICE GUIDELINE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, NON-HODGKIN; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035196082     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Long-term survival in primary CNS lymphoma
2. Selected pharmacologic characteristics of idarubicin and idarubicinol
3. Cytarabine and neurologic toxicity
4. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy
5. Late neurological toxicity after the treatment of primary cerebral lymphoma: Multivariate analysis on 208 patients
6. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression
7. Salvage radiotherapy for immunocompetent primary non-Hodgkin's CNS lymphomas: An Italian study
8. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma
9. Primary central nervous system lymphoma
10. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy
11. Combined modality therapy for primary CNS lymphoma
12. Primary central nervous system lymphoma: Long term results of the GOELAMS LCP 88 trial with a focus on neurological complications among 152 patients
13. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate
14. Primary central nervous system lymphoma in immunocompetent patients
15. Primary central nervous system lymphoma
16. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma
17. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
18. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome
19. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)
20. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
21. PCV salvage chemotherapy for recurrent primary CNS lymphoma
22. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation
23. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry
24. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short-duration response and multifocal intracerebral recurrence preceding radiotherapy
25. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
26. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide
27. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma
28. Activity of rituximab in primary central nervous system lymphoma PCNSL
29. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A Childrens Cancer Study Group report
30. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma
31. Second-line treatment for primary central nervous system lymphoma
32. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia
33. Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
34. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
35. Primary central nervous system lymphoma: Treatment with chemotherapy and radiotherapy
36. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy oncology group protocol 88-06
37. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature
38. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases
39. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma
40. Temozolomide: A candidate for combination with loco-regional radiotherapy